What if a gene-editing cure upends pharma economics?
A gene-editing cure is, like longevity, a thematic repricing the tape barely registers day-one (faint risk-on). The actionable chain is within healthcare: the curative-therapy economics destroy recurring-revenue chronic-treatment franchises (the manufacturer of the displaced standard-of-care) while the platform owner (CRISPR/base-editing) re-rates. Rhymes with the 2017-2019 gene-therapy approvals (Luxturna/Zolgensma) that pressured competing chronic-care names. Skeptic: pricing/reimbursement and durability questions cap the disruption, so size it as a pharma long-short, not a sector bet.
how we built this number — every step
The class rate is measured from our dated, sourced event library (decade-normalized Poisson — the full table is public at base_rates.json). The variant’s share within its class is the analyst’s editorial call, published so you can audit it. A wider range means thinner precedent. Full recipe: methodology · scored at Reality Check.
The butterfly cascade
How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.
Resolution timeline — how this probability is moving
Our model's odds (gold) over time vs the crowd's (Polymarket, blue), from the past toward the 3–10 years horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. The gold path is an illustrative reconstruction anchored to today's estimate — real dated events, not a live re-estimate history.
What it would mean
If this plays out, it is a mixed shock. A gene-editing cure for a major disease disrupts pharma economics. The trigger decomposes into signed root‑shocks — Risk appetite ▲ — which propagate through our causal graph to the markets below.
If it happens — the markets it would move
Biggest moves first. Projected moves are cascade-model priors; hist A–B% = what comparable past events actually did (measured abnormal returns), and model prior · unmeasured marks markets with no analogue backing yet. Tap any market for its price history.
| Market | Class | Projected move | |
|---|---|---|---|
| 1 | Solana SOLon Hyperliquid 📈 chart | Crypto | ▲ +0.3% hist -3.42–+7.2% · other way -5.35% (n=8) |
| 2 | Hyperliquid (HYPE) HYPEon Hyperliquid | Crypto | ▲ +0.3% model prior · unmeasured |
| 3 | MicroStrategy MSTRon Hyperliquid 📈 chart | Equity | ▲ +0.3% hist -6.55–+17.0% · other way +3.07% (n=12) |
| 4 | Ether ETHon Hyperliquid 📈 chart | Crypto | ▲ +0.2% hist -2.35–+6.78% · other way -3.97% (n=11) |
| 5 | Nasdaq 100 NDXon Hyperliquid 📈 chart | Index | ▲ +0.2% hist +0.07–+0.16% · other way +1.97% (n=12) |
| 6 | Bitcoin BTCon Hyperliquid 📈 chart | Crypto | ▲ +0.2% hist -1.84–+4.13% · other way -2.36% (n=12) |
| 7 | Tech sector XLK 📈 chart | Equity | ▲ +0.1% hist +0.01–+0.18% · other way +1.69% (n=12) |
Probable recommendation
Why we may diverge from history
Trust the cascade's BTC long: the -1.8% history is the same palladium/SPX-record beta noise, no gene-editing channel — swamped sample; the pharma-disruption read won't show up in BTC's measured move.
Historical precedent — what analogous events actually did
Across 40 analogous events (overlap‑weighted), as abnormal returns — market beta stripped, so it's the event's own effect, not the market backdrop. Shown at 20 days (persistent) and 5 days (immediate); ↺ fades = the two horizons disagree. Confidence = consistency × sample × significance.
| Asset | History says | Abnormal (20d · 5d) | Hit | n | Confidence | vs cascade |
|---|---|---|---|---|---|---|
| 10y yield DGS10 | LONG | +12bp · 5d +3bp | 70% | 40 | 0.32 | · |
| High-yield credit HYG | SHORT | -0.4% · 5d -0.0% | 66% | 40 | 0.23 | · |
| US dollar DXY | SHORT | -0.1% · 5d -0.1% | 61% | 40 | 0.17 | · |
| ETH ETH | LONG | +6.2% · 5d -2.0% ↺ fades | 59% | 40 | 0.15 | ✓ matches cascade |
| MSTR MSTR | LONG | +15.9% · 5d -0.7% ↺ fades | 57% | 40 | 0.13 | ✓ matches cascade |
| Gold XAU | SHORT | -0.4% · 5d -0.6% | 57% | 40 | 0.11 | · |
| Bitcoin BTC | LONG | +3.9% · 5d -2.1% ↺ fades | 52% | 40 | 0.04 | ✓ matches cascade |
| Volatility VIX | LONG | +0.1% · 5d -4.5% ↺ fades | 52% | 40 | 0.03 | · |
| SOL SOL | LONG | +6.9% · 5d -3.5% ↺ fades | 45% | 40 | 0.00 | ✓ matches cascade |
| NDX NDX | LONG | +0.0% · 5d -0.8% ↺ fades | 43% | 40 | 0.00 | ✓ matches cascade |
| XLK XLK | LONG | +0.1% · 5d -0.5% ↺ fades | 39% | 40 | 0.00 | ✓ matches cascade |
Why this probability
Gene-editing cures advancing (CRISPR approvals); a major-disease cure disrupting pharma plausible over 3-10yr. A base‑rate‑anchored prior, continuously scored against what actually happens — not a forecast.